Shenzhen Pregene Biopharma Co. Ltd

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
      • Molecular Diversity
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies

Other Names/Subsidiaries

  • Pregene
  • Shenzhen Prerigin Biopharmaceutical Co., Ltd.
See more in Biomedtracker

Latest on Shenzhen Pregene Biopharma Co. Ltd

Scrip

Nkarta’s AML Update Disappoints, But New Conditioning Regimen Might Improve Response

 
• By Joseph Haas

More than a year after reporting promising early data for its allogeneic chimeric antigen receptor natural killer (CAR-NK) candidate NKX101 in relapsed/refractory acute myeloid leukemia, Nkarta, Inc.

Scrip

Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies

 
• By Ian Haydock, Anju Ghangurde, Dexter Jie Yan, and Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. $50m Taysha Investment Gives Astel

Scrip

Deal Watch: Lilly Teams With Regor On Metabolic Disorders

 
• By Joseph Haas and Dexter Jie Yan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Doubles Down On Metabolic Disorde

Scrip

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

 
• By Joseph Haas, Dexter Jie Yan, Jung Won Shin, and Anju Ghangurde

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OliX, Hansoh Ink Licensing Pact To Deve